DISCOVER CAMCEVI.
site-logo
AVAILABLE
TO ORDER
 

This site is intended for use by U.S. residents only.

©2023 CAMCEVI. All rights reserved. WS-CAM-2300002

Still the first and only

prefilled leuprolide syringe with no mixing required1

Request a Representative
Request a Representative
See how simple Syringe prep can be
Request a Representative
Request a Representative

Discover Camcevi®

syringe icon
The first and only
CAMCEVI is the first AND ONLY sub-Q leuprolide therapy that comes prefilled with no mixing.1
proven icon
Proven leuprolide efficacy*
CAMCEVI was dosed subcutaneously, 42 mg on Day 0 and again at Week 24, and offers consistent suppression of testosterone to castrate levels from Week 4 to Week 48.1
simple icon
Simplified Preparation
CAMCEVI comes prefilled with no mixing required—simplifying syringe prep for you.1
unique icon
Unique J Code
CAMCEVI has unique J Code J1952

*CAMCEVI was evaluated in an open-label, single arm, multinational study involving 137 patients with advanced prostate cancer with a baseline morning serum testosterone level of >150 ng/dL and ECOG performance status of ≤2. CAMCEVI was dosed subcutaneously, 42 mg on Day 0 and again at Week 24.1

The primary endpoint was medical castration rate, defined as achieving and maintaining serum testosterone suppression to ≤50 ng/dL by Week 4 through Week 48 of treatment after the initial injection.1

SIMPLE ORDERING

We continue to expand our network of distribution partners and GPOs.

Order now

    CONNECT WITH A REPRESENTATIVE

    Complete the forms with your information to reach a CAMCEVI representative near you.

    *Required fields

    IMPORTANT SAFETY INFORMATION

    Do not use CAMCEVI® in patients with hypersensitivity to GnRH, GnRH agonist analogs, or any of the components of CAMCEVI as anaphylactic reactions to these drugs have been reported in the medical literature.

    CAMCEVI, like other GnRH agonists, causes a transient increase in serum levels of testosterone during the first week of treatment which can cause transient worsening of symptoms. As with other GnRH agonists, cases of ureteral obstruction, spinal cord compression, have been observed, which may contribute to paralysis with or without fatal complications.

    Patients with metastatic vertebral lesions and/or with urinary tract obstruction should be closely observed during the first few weeks of therapy.

    Hyperglycemia and an increased risk of developing diabetes have been reported in men receiving GnRH agonists. Blood glucose levels should be monitored and managed according to current clinical practice.

    Increased risk of myocardial infarction, sudden cardiac death, and stroke has been reported in association with the use of GnRH agonists. The risk appears low based on the reported odds ratios and should be evaluated carefully along with cardiovascular risk factors when determining a treatment for patients with prostate cancer. Patients should be monitored for cardiovascular disease and according to current clinical practice.

    Androgen deprivation therapy may prolong the QT interval. Consider periodic monitoring of electrocardiograms and electrolytes.

    Convulsions have been reported in patients receiving GnRH agonists, like CAMCEVI. Patients experiencing convulsions should be managed according to the current clinical practice.

    Monitor serum levels of testosterone following injection of CAMCEVI.

    Based on findings in animal studies and mechanism of action, CAMCEVI may cause fetal harm when administered to pregnant women.

    The most common (≥10%) adverse reactions during a median follow-up of 336 days were hot flush, hypertension, injection site reactions, upper respiratory tract infections, musculoskeletal pain, fatigue, and pain in extremity.

    INDICATION

    CAMCEVI is indicated for the treatment of adult patients with advanced prostate cancer.

    Click here for full Prescribing Information.

    Reference:

    1. CAMCEVI. Prescribing information. Accord BioPharma; May 2021.